Okay, I’ve done the math. I have experienced an estimated 2,880 days of migraine so far in life (12 per month X 20 years). If it wasn’t for the triptan medication I take, all of those days would have been 100% ruined. Many of them weren’t salvaged and the pain and nausea went off the rails. (Thus, the many embarrassing calls I have made to cancel on people, uy).
Enough about my sad saga. This blog is about a new class of drugs – CGRP Drugs – that Dr. Peter McAllister of New England Institute for Neurology & Headache says may be a better match for migraine because they use high-tech molecules that more directly target the root of the migraine.
What is CGRP?
The once-a-month injection blocks the activity of CGRP (calcitonin gene-related peptide), the molecule that’s known to spike during migraine attacks.
“CGRP is a major inflammatory chemical in the brain. And if you can stop CGRP, you can prevent the entire migraine cascade,” says McAllister.
“Where most pills you take will go through the liver and then have non-specific effects. this only goes to the target and it binds to it with a high degree of specificity. It’s almost like a key in a lock,” he says.
Angelo Termine of the New England Institute for Clinical Research says if a migraine sufferer thinks this kind of treatment makes sense for them, he or she can give a call over to speak to a member of the NEICR research team. They’ll work with the caller to figure out if any of the CGRP or other clinical trials that are either underway or just getting started are a fit.
“We have a lot of clinical trials for migraine happening, we have new ones starting up now. The big thing is CGRP,” says Angelo Termine, New England Institute for Clinical Research.
To ask about migraine clinical trials, you can contact New England Institute for Clinical Research at 203/914-1903.
For more detail on the role scientists believe CGRP plays in migraine, click here National Institutes of Health
The post NEW CLASS OF DRUGS TO TURN OFF MIGRAINE AT ROOT – Clinical Trials of CGRP Drugs Accessible Now appeared first on Brain News Brief.